|
An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. Clinical research trials and An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.. An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. clinical trial. Human subjects often receive the most effective healthcare possible for their An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.  An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.
An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.
For Condition: Metastases, Neoplasm,Breast Neoplasms
Status: Terminated
Sponsor(s): Pfizer ,
Synopsis: The purpose of this study is to find out if the two different formulations of an investigational drug, oral and injectable, are equivalent in terms of pharmacodynamics and pharmacokinetics, i.e. if ultimately both formulations have the same efficacy in postmenopausal women with metastatic breast cancer who have failed previous antiestrogens therapy and are equally safe.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Female
Protocol Entry Criteria: Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: Diagnosed with breast cancer Estrogen receptor positivity Postmenopausal status Advanced disease Progression to previous tamoxifen therapy Exclusion Criteria: More than 1 chemotherapy and-or more than 1 hormonotherapy for advanced disease Previous hormonotherapy other than Tamoxifen
Total Enrollment:
Location and Contact Information:
Research Center
Puyallup, Washington, 98372
United States
Research Center
Yakima, Washington, 98902
United States
Research Center
St. Louis, Missouri, 63136
United States
Additional Information:
Study ID Numbers: 971-ONC-0401-003;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00040014
Other Breast Neoplasms Studies:
1. Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent with Metastatic Lung Cancer
2. Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
3. Magnetic-Targeted Doxorubicin in Treating Patients with Cancer Metastatic to the Liver
4. Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
5. This study is to assess the efficacy and safety of ZD6474 in subjects with Non-small cell lung cancer.
Related Studies:
Other Breast Neoplasms Clinical Trials
Other Washington Clinical Trials
Other Puyallup Clinical Trials
An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.
|
|
|
|
|
|
|
|
